SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond – 29 January 2025, 18:00 CET.
Save the date!
Main topics:
∙ Review of the latest HR+ HER2- MBC data and description of the current and future treatment landscape
∙ Biomarker testing.
∙ Biomarker vs non-biomarker driven treatment choices.
∙ Optimal sequencing the current and future dependant on clinical characteristic (which?)
Register now (free of charge).
This webinar is supported by an unrestricted educational grant from Eli Lilly.”